192 related articles for article (PubMed ID: 27243342)
21. V617F JAK-2 mutation in patients with essential thrombocythemia: relation to platelet, granulocyte, and plasma hemostatic and inflammatory molecules.
Falanga A; Marchetti M; Vignoli A; Balducci D; Russo L; Guerini V; Barbui T
Exp Hematol; 2007 May; 35(5):702-11. PubMed ID: 17577920
[TBL] [Abstract][Full Text] [Related]
22. Mutations and thrombosis in essential thrombocythemia: prognostic interaction with age and thrombosis history.
Gangat N; Wassie EA; Lasho TL; Finke C; Ketterling RP; Hanson CA; Pardanani A; Wolanskyj AP; Maffioli M; Casalone R; Passamonti F; Tefferi A
Eur J Haematol; 2015 Jan; 94(1):31-6. PubMed ID: 24889737
[TBL] [Abstract][Full Text] [Related]
23. Clinico-hematological profile and thrombotic/hemorrhagic events in 150 chinese patients with essential thrombocythemia.
Zhou D; Chen W; Cheng H; Qiao JL; Zhu LL; Li ZY; Xu KL
Leuk Res; 2018 Jun; 69():1-6. PubMed ID: 29609040
[TBL] [Abstract][Full Text] [Related]
24. Prediction of thrombotic and hemorrhagic events during polycythemia vera or essential thrombocythemia based on leukocyte burden.
Lim Y; Lee JO; Kim SH; Kim JW; Kim YJ; Lee KW; Lee JS; Bang SM
Thromb Res; 2015 May; 135(5):846-51. PubMed ID: 25743883
[TBL] [Abstract][Full Text] [Related]
25. JAK2 V617F, hemostatic polymorphisms, and clinical features as risk factors for arterial thrombotic events in essential thrombocythemia.
Moreno MJ; Lozano ML; Roldán V; Bellosillo B; García-Barberá N; Rivera J; Navarro-Núñez L; Besses C; Vicente V; Martínez C
Ann Hematol; 2008 Sep; 87(9):763-5. PubMed ID: 18365193
[No Abstract] [Full Text] [Related]
26. High prevalence of heparin induced thrombocytopenia with thrombosis among patients with essential thrombocytemia carrying V617F mutation.
Castelli R; Gallipoli P; Schiavon R; Teatini T; Deliliers GL; Bergamaschini L
J Thromb Thrombolysis; 2018 Jan; 45(1):106-113. PubMed ID: 29022213
[TBL] [Abstract][Full Text] [Related]
27. The evaluation of the relevance of thrombin generation and procoagulant activity in thrombotic risk assessment in BCR-ABL-negative myeloproliferative neoplasm patients.
Baccouche H; Ben Jemaa M; Chakroun A; Chadi S; Mahjoub S; Sfar I; Gorgi Y; Ben Romdhane N
Int J Lab Hematol; 2017 Oct; 39(5):502-507. PubMed ID: 28497580
[TBL] [Abstract][Full Text] [Related]
28. Uncontrolled thrombocytosis in polycythemia vera is a risk for thrombosis, regardless of JAK2(V617F) mutational status.
Ohyashiki K; Akahane D; Gotoh A; Ito Y; Tauchi T; Miyazawa K; Kimura Y; Ohyashiki JH
Leukemia; 2007 Dec; 21(12):2544-5. PubMed ID: 17611562
[No Abstract] [Full Text] [Related]
29. Increased circulating procoagulant activity and thrombin generation in patients with myeloproliferative neoplasms.
Duchemin J; Ugo V; Ianotto JC; Lecucq L; Mercier B; Abgrall JF
Thromb Res; 2010 Sep; 126(3):238-42. PubMed ID: 20656333
[TBL] [Abstract][Full Text] [Related]
30. Comparison of clinicopathologic findings according to JAK2 V617F mutation in patients with essential thrombocythemia.
Cho YU; Chi HS; Lee EH; Jang S; Park CJ; Seo EJ
Int J Hematol; 2009 Jan; 89(1):39-44. PubMed ID: 19093167
[TBL] [Abstract][Full Text] [Related]
31. Evaluation of the prevalence and prospective clinical impact of the JAK2 V617F mutation in coronary patients.
Muendlein A; Gasser K; Kinz E; Stark N; Leiherer A; Rein P; Saely CH; Grallert H; Peters A; Drexel H; Lang AH
Am J Hematol; 2014 Mar; 89(3):295-301. PubMed ID: 24265174
[TBL] [Abstract][Full Text] [Related]
32. Markers of myeloproliferative diseases in childhood polycythemia vera and essential thrombocythemia.
Teofili L; Giona F; Martini M; Cenci T; Guidi F; Torti L; Palumbo G; Amendola A; Foà R; Larocca LM
J Clin Oncol; 2007 Mar; 25(9):1048-53. PubMed ID: 17369568
[TBL] [Abstract][Full Text] [Related]
33. [The JAK2 mutation in myeloproliferative disorders: A predictive factor of thrombosis].
Mahjoub S; Baccouche H; Sahnoun M; Kaabi H; Manai Z; Slama H; Ben Romdhane N
Tunis Med; 2015 Jul; 93(7):474-7. PubMed ID: 26757507
[TBL] [Abstract][Full Text] [Related]
34. Thrombosis can occur at any phase of essential thrombocythemia with JAK2(V617F) mutation: a single institutional study in Japan.
Ohyashiki K; Ito Y; Hori K; Sato K; Makino T; Ohyashiki JH
Leukemia; 2007 Jul; 21(7):1570-1. PubMed ID: 17392820
[No Abstract] [Full Text] [Related]
35. Leukocytosis is a risk factor for thrombosis in essential thrombocythemia: interaction with treatment, standard risk factors, and Jak2 mutation status.
Carobbio A; Finazzi G; Guerini V; Spinelli O; Delaini F; Marchioli R; Borrelli G; Rambaldi A; Barbui T
Blood; 2007 Mar; 109(6):2310-3. PubMed ID: 17110452
[TBL] [Abstract][Full Text] [Related]
36. Clinical and laboratory features, pathobiology of platelet-mediated thrombosis and bleeding complications, and the molecular etiology of essential thrombocythemia and polycythemia vera: therapeutic implications.
Michiels JJ; Berneman Z; Van Bockstaele D; van der Planken M; De Raeve H; Schroyens W
Semin Thromb Hemost; 2006 Apr; 32(3):174-207. PubMed ID: 16673274
[TBL] [Abstract][Full Text] [Related]
37. JAK2 V617F mutational frequency in essential thrombocythemia associated with splanchnic or cerebral vein thrombosis.
De Stefano V; Rossi E; Za T; Ciminello A; Betti S; Luzzi C; Leone G; Chiusolo P
Am J Hematol; 2011 Jun; 86(6):526-8. PubMed ID: 21594892
[No Abstract] [Full Text] [Related]
38. JAK2 V617F mutation status of 232 patients diagnosed with chronic myeloproliferative neoplasms.
Payzin KB; Savasoglu K; Alacacioglu I; Ozdemirkiran F; Mutlu BB; Bener S; Calli AO; Kucukzeybek BB; Aksun S
Clin Lymphoma Myeloma Leuk; 2014 Dec; 14(6):525-33. PubMed ID: 24811089
[TBL] [Abstract][Full Text] [Related]
39. The role of JAK2 V617F mutation, spontaneous erythropoiesis and megakaryocytopoiesis, hypersensitive platelets, activated leukocytes, and endothelial cells in the etiology of thrombotic manifestations in polycythemia vera and essential thrombocythemia.
Bellucci S; Michiels JJ
Semin Thromb Hemost; 2006 Jun; 32(4 Pt 2):381-98. PubMed ID: 16810614
[TBL] [Abstract][Full Text] [Related]
40. Essential thrombocythemia in young individuals: frequency and risk factors for vascular events and evolution to myelofibrosis in 126 patients.
Alvarez-Larrán A; Cervantes F; Bellosillo B; Giralt M; Juliá A; Hernández-Boluda JC; Bosch A; Hernández-Nieto L; Clapés V; Burgaleta C; Salvador C; Arellano-Rodrigo E; Colomer D; Besses C
Leukemia; 2007 Jun; 21(6):1218-23. PubMed ID: 17519959
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
